ImmunoGen seeks $100m funding to surf T-DM1 wave
This article was originally published in Scrip
ImmunoGen hopes to raise $100 million thought a secondary stock offering that is expected to close on 17 July. With its stock trading on 9 July at a 5-year high following the excitement around antibody-drug conjugates, the Waltham, Massachusetts-based hopes to sell 6.25 million shares at $16 to accelerate its targeted anti-cancer therapeutic pipeline. That pipeline is led by its partnership with Roche for the antibody-drug conjugate T-DM1 (trastuzumab emtansine) for the treatment of metastatic breast cancer. Investors, of course, sent ImmunoGen's stock down the 8% that the company had discounted its offering from its previous day's price.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.